Product Description: Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd 50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis[1][2][3].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]McKeage K, Duggan S. Risankizumab: First Global Approval. Drugs. 2019 Jun;79(8):893-900./[2]Andrea Chiricozzi, et al. Risankizumab for the treatment of moderate to severe psoriasis. Expert Opinion on Biological Therapy. Volume 19, 2019 - Issue 1/[3]Singh S, et al. Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7(4):778-91.
CAS Number: 1612838-76-2
Molecular Weight: N/A
Compound Purity: 97.70
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Interleukin Related
English
Deutsch
